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Abstract We compared the clinical findings and survival in
patients withMycobacterium avium complex (MAC) and other
non-tuberculous mycobacteria (NTM). A total of 167 adult non-
human immunodeficiency virus (HIV) patients with at least one
positive culture for NTM were included. Medical records were
reviewed. The patients were categorised according to the 2007
American Thoracic Society (ATS) criteria. MAC comprised
59 % of all NTM findings. MAC patients were more often
female (70 % vs. 34 %, p<0.001) and had less fatal underlying
diseases (23 % vs. 47 %, p=0.001) as compared to other NTM
patients. Symptoms compatible with NTM infection had lasted
for less than a year in 34% ofMACpatients but in 54% of other
NTM patients (p=0.037). Pulmonary MAC patients had a sig-
nificantly lower risk of death compared to pulmonary other
NTM (hazard ratio [HR] 0.50, 95 % confidence interval [CI]
0.33–0.77, p=0.002) or subgroup of other slowly growing
NTM (HR 0.55, 95 % CI 0.31–0.99, p=0.048) or as rapidly
growing NTM (HR 0.47, 95 % CI 0.25–0.87, p=0.02). The
median survival time was 13.0 years (95 % CI 5.9–20.1) for
pulmonaryMACbut 4.6 years (95%CI 3.4–5.9) for pulmonary
other NTM. Serious underlying diseases (HR3.21, 95 % CI
2.05–5.01, p<0.001) and age (HR 1.07, 95 % CI 1.04–1.09,
p<0.001) were the significant predictors of mortality and female
sex was a predictor of survival (HR 0.38, 95 % CI 0.24–0.59,
p<0.001) in the multivariate analysis. PulmonaryMAC patients
had better prognosis than pulmonary other NTM patients. The
symptom onset suggests a fairly rapid disease course.
Introduction
The incidence of non-tuberculous mycobacteria (NTM) in clin-
ical samples has been reported to increase, and they have be-
come a more common finding than classical Mycobacterium
tuberculosis in many countries [1–3]. M. avium complex
(MAC) has been the most commonly found NTM in human
infections in most parts of the world, but in Europe, it makes up
only about one-third of NTM isolations [3–6]. Other NTM
species in clinical findings are all clearly less common but also
variable in different geographical regions. In Europe,
M. gordonae consisted of up to 17 %, rapidly growing
mycobacteria (RGM) 16%,M. xenopi 14% andM.malmoense
1 % of all NTM isolations in 2008 [6]. However, in northern
Europe,M. malmoense has been the second or third most com-
mon isolate [7–9]. In other parts of the world, M. kansasii,
M. abscessus and M. chelonae have been common isolations
and, especially in Asia, RGM have been commonly reported
[4–6]. During the last year, the interest in NTM infections has
increased, with the result of almost an explosion of published
articles. NTM have been reported more often in patients with
underlying diseases like autoimmune diseases and bronchiecta-
sis or cystic fibrosis [1, 10–13]. Almost 10 % of patients with
bronchiectasis have been observed to have NTM and NTM
have been suggested to increase the risk of chronic obstructive
lung disease [12, 14]. Furthermore, NTM have been reported to
be associated with an increased proportion of deaths in USA
and increased risk of respiratory failure [15, 16].
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MAC has generally been considered to be more pathogenic
and more often disease-causing than the other NTM strains
[17–19]. This has resulted in the American Thoracic Society
(ATS) publishing criteria to discern NTM pulmonary disease
from colonisation and the criteria were designed for MAC,
M. kansasii and M. abscessus [17]. However, recent studies
have shown that ATS criteria did not predict fatal outcome in
patients with an NTM isolation [1, 10]. In a population-based
study from Denmark, M. xenopi was associated to poorer
prognosis than MAC [1]. Furthermore, ATS criteria-positive
MAC patients had total mortality of 24 % but MAC-specific
mortality was as low as 5% [20]. Avery recent study observed
that a single isolation ofM. fortuitum in a respiratory specimen
seldom indicated progression of disease and, after single iso-
lations of other NTM species, progression was dependent on
patient age and radiographic changes, but not on the NTM
species [21]. Indeed, the prognostic value of non-MAC
NTM isolation still seems to be largely unclarified.
The clinical picture of disease caused by various NTM spe-
cies has been divergent and even stereotypic in the literature.
MAC has been reported to affect more often female non-
smokers without underlying diseases and to cause either pulmo-
nary nodules or bronchiectasis with less cavities [7, 20, 22].
Patients with M. xenopi infections have generally been de-
scribed as middle-aged smoking males with chronic obstructive
pulmonary disease (COPD) or prior tuberculosis with upper
lobe cavitary infections [23]. M. malmoense has been linked
to fibrocavitary disease with tuberculosis or MAC-like symp-
toms in males with COPD [6]. M. kansasii has been linked to
disease indistinguishable from tuberculosis, with a clear male
predominance [24, 25]. However, several recent follow-up stud-
ies have indicated that pulmonary NTM findings carry a high
mortality rate, ranging from 29 to 69%within 5 years [1, 7, 20].
Most data from disease due to various NTM species come from
studies collecting data from patients with one particular NTM.
Prognosis, symptoms and underlying factors as compared to
MAC with similar setting and follow-up are scarce.
The aim of this study was to ascertain underlying diseases,
symptoms and prognostic factors in relation to mortality in
NTM infections. In this study, firstly, we retrospectively
followed patients with an NTM isolation for, on average,
7 years. Secondly, we evaluated the survival, clinical differ-
ences and characteristics in NTM infections between MAC
and other NTM.
Materials and methods
Study population
Human immunodeficiency virus (HIV)-negative patients with
at least one positive culture finding for NTM from 1990 to the
end of 1998 and from 2004 to the end of 2009 were included in
the study. Samples for mycobacterial culture were analysed by
the Central Microbiological Laboratory of Helsinki City, later
Helsinki University Central Hospital Laboratory (HUSLAB),
and patients were identified and matched with their records and
isolates by using their unique personal identity number; these
numbers are given to all residents of Finland.
All patients had been referred to a pulmonary specialist in
some of the eight different hospitals in the area of Helsinki
University Central Hospital because of pulmonary symptoms
compatible with NTM infection. One patient with concomitant
findings of M. tuberculosis and M. avium was excluded. Alto-
gether, 167 patients (adults aged 16–94 years) were included in
the study population. The patient material has been, in part,
presented in our previous studies [7, 26]. For analyses of pul-
monary NTM infection, all six patients with a cutaneous NTM
isolation were excluded. The numbers of subsequent positive or
negative mycobacterial smears, cultures and sampling sites
were recorded. Demographic characteristics (age, sex, occupa-
tion, body weight, height) were obtained from the patient re-
cords. The concomitant diseases were classified as described by
McCabe and Jackson [27] as follows: (1) healthy, i.e. no other
diseases; (2) chronic non-fatal diseases; (3) ultimately fatal dis-
eases with expected life expectancy of 5 years maximum, such
as carcinoma with local spreading and uncompensated hepatic
cirrhosis; (4) rapidly fatal diseases with expected survival of no
more than 6 months, such as carcinoma with widespread me-
tastases. In particular, information on previous pulmonary dis-
eases, such as bronchiectasis, COPD, pulmonary fibrosis, prior
tuberculosis, asthma, pulmonary malignancies and pneumo-
nias, were retrieved. The signs, symptoms, microbiological data
and other laboratory findings were all reviewed at the time of
the first positive NTM culture and at patient visits closest
(6 months) to 1 year after the positive culture. The radiological
findings of chest X-ray, computed tomography (CT) scans and
high-resolution computed tomography (HRCT) were collected
from the original radiologist statements at patient visits closest
(6 months) to 1 year after the positive culture and classified as
infiltrates, nodules, cavities or bronchiectasis according to the
2007 ATS criteria [17]. Only data relevant to ATS criteria were
collected, and in unclear cases, a radiologist was consulted.
Previous (6 months) immunosuppressive treatments were
reviewed. Systemic or inhalation corticosteroid treatment was
recorded when continued for longer than 1 month. Information
on previous pulmonary diseases was retrieved. Data on
smoking habits were retrieved from the medical records and
pulmonary function test questionnaires. The date of death was
ascertained from the Finnish Population Register Centre re-
cords or patient records.
Microbiological methods
Clinical specimens, except for blood samples, were stained
with auramine-O-fluorochrome dye and examined
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microscopically for acid-fast bacilli (AFB). Cultures positive
for AFB were identified by conventional biochemical tests
and hybridisation with DNA probes (AccuProbe; Gen-Probe,
San Diego, CA, USA). Cultures negative for M. tuberculosis
and MAC were identified by amplification and sequencing of
the 16S rRNA gene. For those NTM patients with a positive
culture finding for NTM from 2004 to the end of 2009, cul-
tures positive for AFB were identified by DNA strip assays
(GenoType Mycobacterium CM/AS, Hain Lifescience,
Nehren, Germany). MAC, M. avium, and M. intracellulare
were all classified as MAC due to changing nomenclature
during the study period.
Case definitions
The NTM patients were categorised according to the 2007
ATS criteria [25] in order to reveal how many fulfilled the
ATS diagnosis for NTM disease. ATS-positive patients had
to meet microbiological, radiological and symptoms criteria.
According to these diagnostic criteria, a patient should have
the NTM isolated in at least two sputum cultures or one pos-
itive culture from a bronchoscopy sample (by lavage or by
brush) or from a lung biopsy to fulfill the microbiological
criteria. One positive culture from a skin or lymphatic tissue
biopsy fulf i l led the microbiological cr i ter ia for
extrapulmonary disease. Radiographic criteria were fulfilled
when nodular or cavitary opacities were found on chest radio-
graphs or CT, or when bronchiectasis with multiple small
nodules were found by CT/HRCT. The patient had to have
symptoms compatible with NTM disease and they included:
cough, dyspnoea, fatigue, fever, weight loss, haemoptysis or
decreased appetite. If the patient did not meet these microbi-
ological, radiographic and symptomatic criteria, he/she was
categorised as ATS-negative.
Statistical methods
The patients having MAC were compared to patients with
other NTM strains. The independent samples t-test was used
for continuous variables. TheMann–WhitneyU-test was used
if the assumption of normality was not achieved using trans-
formations. The Chi-squared test and Fisher’s exact test were
used for categorical variables. The Kaplan–Meier method was
used to estimate the median survival times with 95 % confi-
dence intervals (CIs). The univariate Cox proportional hazards
model was used to compare the survival times of the MAC
patients to the patients with other NTM strains. Also, the sur-
vival times between different mycobacterial species and
groups of species were compared. The results are given as
hazard ratios (HRs) with 95 % CIs. In addition, two
predefined adjusted survival time comparisons between
MAC and other NTM strains were conducted, including
ATS 2007 positivity (positive vs. negative) and underlying
diseases according to the McCabe classification (3–4 vs. 1–
2) as additional dichotomous covariates. The interactions were
tested including appropriate interaction terms in the models. In
the next phase, smoking, fulfilment of ATS 2007 criteria, un-
derlying diseases according to the McCabe classification (1–2
or 3–4), age, gender and smoking were considered as potential
additional predictors, as they were all significant predictors in
the univariate models. They were introduced to the forward
stepwise (criterion for entry p<0.05) multivariate Cox propor-
tional hazards model. The assumption of proportional hazards
was graphically assessed. We obtained plots of log (log S(t))
versus time in order to see the difference between the survival
curves. If the survival curves were approximately parallel,
then the proportionality assumption was reasonable. Based
on those graphical plots, the proportionality assumption was
not rejected for any predictor. The number of multivariate
analyses was three. They were performed according to the
predefined analysis plan. Other multivariate analyses were
mainly exploratory or stepwise Cox models using different
variable selection methods (different cut-off values for p-
values and different blocks of variables). These additional
models were performed in order to confirm the results. The
predictors in the three final models were: (1) multivariate
model with two predictors: fulfilment of MAC and fulfilment
of ATS 2007 criteria (Fig. 2, panel A). (2) Multivariate model
with two predictors: fulfilment of MAC and underlying dis-
eases according to theMcCabe classification (Fig. 2, panel B).
(3) Age, gender, smoking, McCabe classification, ATS 2007
fulfilment and MAC fulfilment were introduced as potential
predictors to the stepwisemultivariatemodel. Three predictors
were selected: McCabe classification, age and gender. Analy-
sis were performed using IBM SPSS Statistics for Windows
(version 21.0; IBM Corp., Armonk, NY, USA).
Results
Mycobacterial strains and patient characteristics
MAC comprised the majority (99/167, 59 %) of all NTM
findings. Other NTM were isolated in 68 (41 %) patients.
RGMM. fortuitum,M. chelonae andM. abscessus comprised
13 % (22/167) of all NTM findings and M. malmoense 9 %
(15/167).M. gordonaewas found in 10% (16/167),M. xenopi
in 2 % (4/167), M. marinum and M. terrae in 1 % of cases
each (2/167). M. paraffinicum and M. triplex were both cul-
tured in one patient (1 %) and other non-specified NTM spe-
cies in five patients (3 %). Two cases of bothM. fortuitum and
M. marinum were cultured from skin, like one M. chelonae
and one non-specified NTM species, which were not included
in the mortality analyses for pulmonary NTM infection.
The mean age of the patients was 66 (range 16–94) years,
with no difference between MAC and other NTM patients
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(Table 1). The majority of MAC patients were female (70 %),
whereas only 34 % of patients with other NTM were female
(p<0.001). MAC patients were more lean than other NTM
patients, as assessed by the body mass index (BMI, 20.3 kg/
m2 vs. 22.9 kg/m2, respectively, p=0.001). There were also
other significant differences between MAC and other NTM
patients; MAC patients had less often fatal underlying dis-
eases (23 % vs. 47 %) or a malignancy (12 % vs. 22 %) but
more often bronchiectasis (25 % vs. 7 %), more often inhala-
tion corticosteroid use (27 % vs. 13 %) and they were more
often non-smokers (58 % vs. 29 %) as compared to patients
with other NTM (Table 1).
Symptoms and clinical findings on presentation
Symptoms compatible with NTM disease had lasted for less
than a year in 34 % of MAC patients but in 54 % of patients
with other NTM (p=0.01, Table 2). Cough was the most com-
mon symptom, reported by 77% of all patients. MAC patients
had more often systemic symptoms like fever (48 % vs. 31 %,
p<0.02) and fatigue (47 % vs. 32 %, p=0.05) as compared to
patients with other NTM.
Only one patient with M. marinum isolated from skin had
normal chest X-ray, whereas all the other patients in both
groups who had chest X-ray taken had pathological findings
(Table 3). There were significantly more patients with nodules
in CT or HRCT in the MAC group (34 %) compared with the
other NTM group (13 %, p=0.003, Table 3). Also, bronchi-
ectasis was more common in MAC than other NTM patients
(31 % vs. 13 %, p=0.009, Table 3), whereas infiltrates (42 %
vs. 40 %) and cavities (10 % vs. 6 %) were not significantly
different between the groups. The radiological findings were
concentrated in the right upper and middle lobes in both
groups, without any significant difference (Table 3). Diffuse
Table 1 Characteristics and
underlying diseases of 167
patients with at least one isolation
of non-tuberculous mycobacteria
(NTM) categorised according to
Mycobacterium avium complex
(MAC) and other NTM species
MAC, n=99 Other NTM, n=68 Total, n=167 p-Value
nb (%) nb (%) nb (%)
Age, mean years (SD) 65.6 (14.4) 66.7 (13.3) 66.0 (13.9) 0.62a
BMIc, kg/m2 mean (SD) 20.3 (3.7) 22.9 (4.3) 21.3 (4.2) 0.001a
Female 69 (70) 23 (34) 92 (55) <0.001d
Underlying diseasese
Healthy or non-fatal disease 76 (77) 36 (53) 112 (67) 0.001d
Ultimately or rapidly fatal disease 23 (23) 32 (47) 55 (33)
Underlying pulmonary diseases
Bronchiectasis 25 (25) 5 (7) 30 (18) 0.003d
COPDf 23 (23) 21 (31) 44 (26) 0.27d
Prior tuberculosis 16 (16) 13 (19) 29 (17) 0.62d
Lung fibrosis 8 (8) 9 (13) 17 (10) 0.28d
Asthma 14 (14) 11 (16) 25 (15) 0.72d
Other pulmonary disease 16 (16) 19 (28) 35 (21) 0.07d
Pulmonary or other malignancy 12 (12) 15 (22) 27 (16) 0.09d
Any previous pulmonary diseases 72 (73) 52 (76) 124 (74) 0.59d
Autoimmune diseases 11 (11) 10 (15) 21 (13) 0.49d
No alcohol abuse 94 (95) 60 (88) 154 (92) 0.11d
Non-smoker 57 (58) 20 (29) 77 (46) <0.001d
Corticosteroid >1 month 25 (26) 18 (27) 43 (26) 0.85d
Corticosteroid inhalation >1 month 26 (27) 9 (13) 35 (21) 0.04d
Immunosuppressive therapy 8 (8) 8 (12) 16 (10) 0.43d
ATS 2007-positive 60 (61) 33 (49) 93 (56) 0.12d
a t-Test for independent samples
b Values are expressed as n (%), unless otherwise stated
c Body mass index, kg/m2
d Chi-squared test
e Underlying diseases classified according to the criteria of the McCabe classification [27]: (1) healthy, i.e. no
other diseases; (2) non-fatal chronic diseases; (3) ultimately fatal diseases with maximum life expectancy of
5 years; (4) rapidly fatal diseases with expected survival for no more than 6 months
f Chronic obstructive pulmonary diseases
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pulmonary findings in the MAC group were more common
than in the other NTM group (29 % vs. 15 %, p=0.03,
Table 3).
There were no differences in elementary laboratory tests
like haemoglobin, alkaline phosphatase and alanine transam-
inase levels between the groups (data not shown). The median
C-reactive protein (CRP) was 11.0 mg/L (interquartile range,
IQR 2.5–45.0) and the median erythrocyte sedimentation rate
was 25 mm/h (IQR 11–58) in the MAC group and the corre-
sponding median CRP and erythrocyte sedimentation rate
were 18.0 mg/L (IQR 5.0–42.0) and 21 mm/h (IQR 11–42)
in the group with other NTM.
Mortality and follow-up
The median follow-up time of these patients was 7.0 (range
0.1–24.5) years, without significant differences between the
study populations (6.1 years in patients from 1990 to 1998 vs.
7.4 years in patients from 2004 to 2009, p=0.12). The follow-
up time was at least 5 years in 63.5 % of all patients (60.0 % in
patients from 1990 to 1998 vs. 72.3% in patients from 2004 to
2009, p=0.14). Patients with pulmonary MAC had a signifi-
cantly lower risk of death as compared to patients with
pulmonary infection of other NTM (HR 0.50, 95 % CI 0.33-
0.77, p=0.002, Fig. 1, panel A). Themedian survival timewas
13.0 years (95 % CI 5.9–20.1) for pulmonary MAC patients
and 4.6 years (95 % CI 3.4–5.9) for pulmonary other NTM
patients (Fig. 1, panel A). Patients with pulmonary MAC also
had significantly lower risk of death as compared to patients
with pulmonary infection due to other slowly growing NTM
(M. malmonese, M. xenopi, M. paranifficum, M. terrae,
M. triplex) (HR 0.55, 95 % CI 0.31–0.99, p=0.048, Fig. 1,
panel B. Also, when compared to patients with pulmonary
infection caused by RGM, the risk of death was lower with
pulmonary MAC patients (HR 0.47, 95 % CI 0.25–0.87, p=
0.02, Fig. 1, panel C).
Further, subgroup analysis was done to compare the
risk for fatal outcome between pulmonary MAC patients
and patients with pulmonary infection due to some de-
fined NTM species. Patients with pulmonary MAC had
a significantly lower risk of death as compared to pulmo-
nary M. fortuitum (HR 0.46, 95 % CI 0.22–0.98, p=
0.045) but not a significantly different risk of death as
compared to patients with M. malmoense (HR 0.64,
95 % CI 0.31–1.31, p=0.22) or M. gordonae (HR 0.64,
95 % CI 0.31–1.31, p=0.22, Fig. 1, panel D).
Table 2 Symptoms and signs at
the time of the first positive NTM
isolation in 167 patients
categorised according to MAC
and other NTM species
MAC, n=99 Other NTM, n=68 Total, n=167 p-Value
nb (%) nb (%) nb (%)
Duration of symptoms
<1 year 33 (34) 37 (54) 70 (43) 0.01a,c
1–2 years 35 (36) 18 (26) 53 (32)
3–10 years 17 (18) 10 (15) 27 (16)
>10 years 11 (12) 3 (4) 14 (9)
Respiratory symptoms
Cough 79 (80) 49 (72) 128 (77) 0.25a
Dyspnoea 53 (54) 32 (47) 85 (51) 0.41a
Haemoptysis 25 (25) 13 (19) 38 (23) 0.35a
Systemic symptoms
Fatigue 47 (47) 22 (32) 69 (41) 0.05a
Fever >37.5 °C 48 (48) 21 (31) 69 (41) 0.02a
Weight loss 32 (32) 17 (25) 49 (29) 0.31a
Non-specific symptoms
Decreased appetite 13 (13) 11 (16) 24 (14) 0.58a
Palpitation 12 (12) 9 (13) 21 (13) 0.83a
Chest pain 14 (14) 10 (15) 24 (14) 0.92a
Arthralgia 7 (7) 5 (8) 12 (7) 1.00d
Night sweats 7 (7) 1 (1) 8 (5) 0.14d
Lymphadenitis 4 (4) 4 (6) 8 (5) 0.72 d
a Chi-squared test
b Values are expressed as n (%) patients with valid information, unless otherwise stated
c The categories 1–2, 3–10 and >10 years were combined before analysis
d Fisher’s exact test
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Among the other NTM group, three analyses were per-
formed using the whole follow-up time and the follow-up time
restricted to the first 3 and 5 years. RGMwas chosen to be the
reference group. There was no significant difference in sur-
vival between RGM, M. gordonae or M. malmoense during
the first 3 years (p=0.85). Also, the pairwise comparisons to
RGM were non-significant (HR0.77, 95 % CI 0.26–2.29, p=
0.64 and HR0.77, 0.26–2.28, p=0.63 for M. gordonae and
M. malmoense, respectively). During the first 5 years, the
difference was also non-significant (p=0.63), and the pairwise
comparisons to RGM were HR0.99, 95 % CI 0.40–2.47, p=
0.99 and HR0.61, 95 % CI 0.21–1.76, p=0.36 for
M. gordonae and M. malmoense, respectively. During the
whole follow-up time, the global test was non-significant
(p=0.90) and the pairwise comparisons were also non-
significant (HR0.89, 95 % CI 0.38–2.07, p=0.79 and HR
0.82, 95 % CI 0.36–1.90, p=0.65 for M. gordonae and
M. malmoense as compared RGM, respectively).
When fulfilment of MAC and fulfilment of ATS 2007
criteria were predictors in the same multivariate Cox pro-
portional hazards model, the survival among the MAC
group (n=99) was significantly higher than in the other
NTM group (n=68) (HR0.57, 95 % CI 0.37–0.88, p=
0.01, Fig. 2, panel A) and, among the ATS 2007-
positive patients, the survival tended to be higher than
among the ATS 2007-negative patients (HR0.66, 95 %
CI 0.44–1.01, p=0.06, Fig. 2, panel A). The interaction
term between these two predictors was non-significant
(p=0.89) and was excluded from the multivariate model.
Furthermore, when fulfilment of MAC and fatal underly-
ing diseases (McCabe 3–4 vs. 1–2) were predictors in the
same multivariate Cox proportional hazards model, the
MAC group had significantly better survival than the oth-
er NTM group (HR0.65, 95 % CI 0.42–1.00, p=0.048,
Fig. 2, panel B) and patients with McCabe 3–4 had sig-
nificantly worse survival than patients with McCabe 1–2
(HR3.33, 95 % CI 2.16–5.12, p<0.001, Fig. 2, panel B).
The interaction term between these two predictors was
non-significant (p=0.24) and was excluded from the mul-
tivariate model. According to univariate analyses, gender,
age and smoking were also significant predictors for fatal
outcome (HR 0.40, 95 % CI 0.26–0.62, p<0.001 for fe-
male gender, HR 1.05, 95 % CI 1.03–1.07, p<0.001 for
age in years and HR 1.69, 95 % CI 1.10–2.60, p=0.02 for
Table 3 Radiological findings
during the first year after NTM
isolation in 167 patients
categorised according to MAC
and other NTM species
MAC, n=99 Other NTM, n=68 Total, n=167 p-Value
nb (%) nb (%) nb (%)
Radiological examinations
Normal X-ray 0 (0) 1 (1.5) 1 (1) 0.40e
Abnormal X-ray 93 (94) 61 (90) 154 (92)
No X-ray 6 (6) 6 (9) 12 (7) 0,.55e
No CT or HRCTc 44 (44) 32 (47) 76 (46) 0.74a
Abnormal CT or HRCT 55 (56) 36 (53) 91 (55)
Radiographical findingsd
Infiltrates 39 (42) 25 (40) 64 (41) 0.84a
Nodules 32 (34) 8 (12) 40 (26) 0.003a
Cavities 9 (10) 4 (6) 13 (8) 0.48a
Bronchiectasis 29 (31) 8 (13) 37 (24) 0.009a
Missing information 6 (6) 6 (9) 12 (7) 0.55e
Location of radiographical findingsd
Right upper lobe 36 (38) 21 (31) 57 (35) 0.42a
Right middle lobe 27 (28) 17 (25) 44 (27) 0.70a
Right lower lobe 17 (18) 10 (15) 27 (17) 0.64a
Left upper lobe 13 (14) 13 (19) 26 (16) 0.32a
Left lower lobe 20 (21) 15 (22) 35 (21) 0.81a
Diffuse findings in both lungs 28 (29) 10 (15) 38 (23) 0.03a
Missing information 3 (3) 1 (2) 4 (2) 0.65e
a Chi-squared test
b Values are expressed as n (%) patients with valid information
cCT computed tomography; HRCT high-resolution computed tomography of the lungs
dMultiple locations were possible
e Fisher’s exact test
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smoking). Thus, in addition to fulfilment of MAC, the
forward stepwise multivariate Cox model (with p <
0.05) included gender, age, smoking, McCabe classifica-
tion and ATS 2007 fulfilment as potential predictors.
According to this multivariate stepwise model, the only
and equally important predictors, were ultimately or rap-
idly fatal disease (McCabe 3–4) (HR3.21, 95 % CI
2.05–5.01, p<0.001), age in years (HR 1.07, 95 % CI
1.04–1.09, p<0.001) and female sex (HR 0.38, 95 % CI
0.24–0.59, p<0.001). Thus, fulfilment of MAC or ATS
2007 criteria did not significantly improve the prediction
model when McCabe classification, age and gender
were already included.
Discussion
Knowledge on the prognostic factors in NTM infection is lim-
ited. Predictors of mortality among NTM infection are unclear
and the pathogenicity of various NTM species may be variable.
In this study, we observed that patients with MAC had signifi-
cantly better prognosis as compared to patients with other NTM
infections. Pulmonary MAC patients had significantly lower
risk of death as compared to patients with pulmonary infection
of other slowly growing NTM and as compared to patients with
pulmonary RGM. The main predictors of mortality in our study
were both ultimately and rapidly fatal underlying diseases, older
age and male gender. The findings are consistent with
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Fig. 1 Kaplan–Meier survival curves for patients having at least one
pulmonary isolation of various non-tuberculous mycobacteria (NTM).
Panel A: Mycobacterium avium complex (MAC) (n=99) compared to
all other NTM species (n=62). The univariate Cox proportional hazards
model was applied for the comparison of MAC vs. other NTM; hazard
ratio (HR) 0.50, 95% confidence interval (CI) 0.33–0.77, p=0.002.Panel
B: MAC (n=99) vs. subgroup 1 of other slowly growing NTM species,
including M. malmoense, M. xenopi, M. paranifficum, M. terrae and
M. triplex (n=23). MAC vs. subgroup 1; HR 0.55, 95 % CI 0.31–0.99,
p=0.048. Panel C: MAC (n=99) vs. a subgroup of rapidly growing
mycobacteria (RGM), including M. fortuitum, M. chelonae and
M. abscessus (n=19). MAC vs. RGM; HR 0.47, 95 % CI 0.25–0.87,
p=0.02. Panel D: MAC (n=99) vs. the most common other NTM
(M. fortuitum n=12, M. malmoense n=15 or M. gordonae n=16).
MAC vs. M. malmoense; HR 0.64, 95 % CI 0.31–1.31, p=0.22. MAC
vs. M. gordonae; HR 0.64, 95 % CI 0.31–1.31, p=0.22. MAC vs.
M. fortuitum; HR 0.46, 95 % CI 0.22–0.98, p=0.045
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prognostic factors in recent studies [1, 20]. In another recent
study, haemoptysis and consolidation in radiological imaging
were also found to be signs of poor prognosis [28].
Somewhat surprisingly, in our study, the patients with
other NTM had worse prognosis than MAC patients. In
accordance with our results, in a recent study, M. xenopi
was found to be related to poorer prognosis as compared
to MAC [1]. The overall mortality of our MAC patients
(median survival of 13.0 years) and other NTM patients
(median survival of 4.6 years) corresponded to those ob-
served in recent studies [1, 20]. These results challenge
our current view on NTM infections where MAC has
been regarded as the main pathogen.
Ultimately and rapidly fatal underlying diseases were the
main predictors for mortality and seemed to be the major
predisposing factors for infection due to other NTM in our
material. Further, MAC patients had significantly less severe
underlying diseases and they were more often non-smoking
females as compared to other NTM patients. In a subgroup
analysis, which included only patients without any fatal un-
derlying diseases, the Kaplan–Meyer survival curves for
MAC and other NTM patients were almost superimposable
during the 8 years of follow-up (Fig. 2, panel B). Yet, MAC
patients who had a fatal underlying disease seemed to have
better prognosis than those with isolation of other NTM
(Fig. 2, panel B). MAC patients had better outcome than the
other NTM patients, even when severe underlying diseases
were taken into account in the Cox proportional hazards mod-
el analysis. However, it has to be pointed out that 77 % of
MAC and 53 % of other NTM patients did not have any fatal
underlying diseases.
We could not highlight any single underlying disease be-
hind NTM infections, because we did not test single underly-
ing diseases statistically. However, 74 % of patients in both
groups had a previous pulmonary disease. Equally, smoking
seemed to be common among our patients. Two-thirds of the
other NTM group and less than half of the MAC group were
smokers. Smoking was related, for the most part, to male
gender, COPD and systemic or inhaled corticosteroid treat-
ment. In a recent study, COPD and corticosteroid treatment
was found to be strong risk factors for NTM disease [29].
However, which comes first, the hen or the egg, has evidently
not been settled and, at least in some patients, it might be
asked whether it is NTM disease or COPD that precedes the
other. Namely, NTM infection was suggested to be one of the
risk factors for COPD [30]. Heavy smoking history has been
previously related to M. malmoense and M. xenopi infection,
but the two other common isolations in our material,
M. chelonae and M. fortuitum, have not been related to
smoking to the same extent [8, 17, 23, 31]. Plausibly, smoking
is a contributing factor in the prognosis of NTM infection.
This could also partly explain the difference in outcome be-
tween MAC and other NTM, as MAC patients were more
often female and over half of them were non-smokers, as also
described in other studies [22, 32, 33]. The result of ATS
criteria fulfilment as a predictor of mortality was controversial
when compared to their original idea. Although ATS criteria
have been used to select patients for antimycobacterial treat-
ment, ATS criteria fulfilment was not a marker for poor but
rather improved prognosis in both MAC and other NTM
groups (Fig. 2, panel A). This observation is in line with our
previous finding with partly the same patient material and also
with a larger registry-based material [1, 10]. Unfortunately,
one limitation of this retrospective and descriptive study was
that we cannot discern what contribution the NTM infection
had in the fatal outcome of the patients and which deaths were
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Fig. 2 Kaplan–Meier survival curves for all patients with at least one
isolation of MAC (n=99) or other NTM species (n=68). Panel A:
grouped according to American Thoracic Society (ATS) 2007 criteria
fulfilment as either positive or negative. The multivariate Cox proportion-
al hazards model yielded a significant effect for MAC (HR0.57, 95 % CI
0.37–0.88, p=0.01). The effect of ATS 2007 positivity was non-
significant (HR0.66, 95 % CI 0.44–1.01, p=0.06). Panel B: grouped
according to those with fatal underlying diseases (McCabe 3–4) or with-
out fatal underlying diseases (McCabe 1–2). The multivariate Cox pro-
portional hazards model yielded a significant effect for MAC (HR0.65,
95 % CI 0.42–1.00, p=0.048) and for McCabe 3–4 (HR3.33, 95 % CI
2.16–5.12, p<0.001)
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due to other causes. Plausibly, severe underlying diseases ex-
plain the mortality rate in ATS-negative patients. The lack of
severe underlying diseases may be one explaining factor be-
hind the better prognosis of MAC (Fig. 2, panel B).
The short time interval from symptom onset in our study
suggests, together with the poor prognosis, that NTM infec-
tions are more rapid than generally emphasised. Overall, in
43 % of the patients, symptoms had lasted for less than a year
and in 75 % less than 2 years before the first positive NTM
culture (Table 3). Of the respiratory symptoms in this study,
dyspnoea was complained by half of all patients already when
NTM was isolated, which is consistent with other studies [34].
The short time frame from symptom onset is consistent with a
recent nationwide cohort study, which suggested that respirato-
ry failure may appear in the first 6 months post-diagnosis and
the risk is greater among NTM patients with COPD or MAC
[16]. Moreover, pulmonary infections due to M. xenopi or
M. malmoense and infections due to M. chelonae or
M. abscessus among organ transplant patients have been re-
ported to progress to death within a few years [8, 23, 29, 35,
36]. Interestingly, other NTM infections in our study had a
short symptom duration more often than MAC. Systemic
symptoms such as fever, fatigue and lower BMI in our MAC
patients would all also comply with the longer disease duration
in MAC as compared to other NTM. This would fit into
prolonged disease history in MAC because low BMI in NTM
disease has been associated to abnormal control of leptin and
adipokines, suggesting a prolonged disease history [30, 32].
M. malmoensewas the third most common NTM isolation,
as could be expected and as reported in other studies from
Nordic countries [8, 9, 37]. However, RGM (M. fortuitum,
M. chelonae, M. abscessus) together formed one-third of all
the other NTM isolations. M. gordonae was common in can-
cer patients. It is often regarded a contamination and its role in
clinical infections has been questioned, although it has been
reported in patients with cancer or immunosuppression [17].
Although our material was small for detailed analyses be-
tween NTM strains, we did not observe any difference in
prognosis between patients withM. malmoense,M. gordonae
and RGM isolations. Although the precise role of NTM infec-
tion for the poor prognosis is still open, it would warrant
studies on the effect of medical treatment on prognosis. Name-
ly, in our previous analysis, we could look for the effect of
treatment of 3 months with at least two effective drugs and
found it to have no effect on prognosis [10]. Accordingly, in a
recent analysis on only MAC disease, antimycobacterial ther-
apy was not found to affect prognosis [20]. Clearly, studies on
the effect of adequate treatment on the outcome on NTM
infection in immunocompetent patients would be needed
and the present study cannot give any answer on this. The
effect of treatment of severe underlying diseases in the out-
come of NTM patients has not been studied either. However,
in recent studies, COPD, bronchiectasis and interstitial
pulmonary diseases were related to high mortality in patients
with NTM infection [15, 38].
Our data show that, together with other recent studies,
NTM isolation was a sign of poor prognosis. Pulmonary
MAC patients had better prognosis than patients with pulmo-
nary infection due to other NTM. In one-third of MAC pa-
tients and a half of other NTM patients, NTM isolation was
made within a year of symptom onset, suggesting a fairly
rapid disease course. Underlying diseases were the main ex-
planation for poor prognosis. Patients who fulfilled the ATS
criteria had better prognosis than ATS-negative patients. The
results indicate that the current understanding on the impor-
tance of an NTM isolation is insufficient.
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